Former Chief Executive Officer · Kalaris Therapeutics, Inc. (KLRS)

Diana Brainard

A named executive officer of Kalaris Therapeutics in every fiscal year CompBrief holds from FY2021 to FY2024. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2024

$3,028,669

Salary $610,638Stock awards $0

FY2023: $6,056,943

1st of 5 named executive officers at Kalaris Therapeutics by FY2024 total.

5 named officers on file for Kalaris Therapeutics, FY2024

Diana Brainard’s pay file — $29

  • 4 fiscal years of pay, line by line
  • 1 equity grant, each cited to its filing

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Kalaris Therapeutics’s whole pay program stands against its peers

  • Kalaris Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on KLRS→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed July 1, 2025 (DEF 14A).

Free

Get Diana Brainard’s full pay file as a PDF — free

More than this page: up to 10 years of Diana’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Diana Brainard compensation by year

Kalaris Therapeutics Summary Compensation Table · all 4 fiscal years held
In US dollars, as Kalaris Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2021FY2022FY2023FY2024
Salary$365,000$604,992$623,432$610,638
Bonus$0$0$0$0
Stock awards$4,748,000$3,899,006$2,211,125$0
Option awards$9,085,643$4,327,381$3,209,186$0
Non-equity incentive$350,400$361,800$0$0
Pension and deferred compensation$0$0$0$0
All other$587,078$12,200$13,200$2,418,031
Total$15,136,121$9,205,379$6,056,943$3,028,669

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Kalaris Therapeutics, Inc. DEF 14A filed July 1, 2025, accession 0001193125-25-153439, and prior-year filings.

How this page was built: the Kalaris Therapeutics, Inc. filed document, accession 0001193125-25-153439. Every figure is read from that document and cited to the page and table it appears in. Filed July 1, 2025.

$15.1M
$9.2M
$6.1M
$3.0M
FY21
FY22
FY23
FY24
SalaryNon-equity incentiveStock awardsOption awardsAll other

Kalaris Therapeutics’s named executive officers, FY2024

as the company reported each
Named executive officerRoleFY2024 total
Diana Brainard · this pageFormer Chief Executive Officer$3,028,669
Andrew OxtobyPresident and Chief Executive Officer$1,965,153
Brett HagenChief Accounting Officer and AlloVir’s former Chief Accounting Officer$796,311
Edward MillerFormer General Counsel and Secretary$645,693
Vikas SinhaAlloVir’s Former Chief Executive Officer, President and Chief Financial Officer$544,400

Board service

Kalaris Therapeutics board · FY2023

How this board is paid

Company policy: Kalaris Therapeutics pays directors a $40,000 cash retainer. As stated in Kalaris Therapeutics's FY2023 proxy.

The full Kalaris Therapeutics compensation record

free company brief

This page is one person within Kalaris Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Kalaris Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Diana Brainard's compensation dossier · One-time report. No refunds.